Logo image of MKD

MOLECULAR DATA INC - ADR (MKD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MKD - US60852L2051 - ADR

0.41 USD
+0.01 (+2.5%)
Last: 9/6/2022, 8:13:10 PM
0.421 USD
+0.01 (+2.68%)
After Hours: 9/6/2022, 8:13:10 PM
Fundamental Rating

1

Overall MKD gets a fundamental rating of 1 out of 10. We evaluated MKD against 0 industry peers in the Internet & Direct Marketing Retail industry. MKD may be in some trouble as it scores bad on both profitability and health. MKD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MKD had negative earnings in the past year.
MKD Yearly Net Income VS EBIT VS OCF VS FCFMKD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA -42.99%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MKD Yearly ROA, ROE, ROICMKD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 1K -1K

1.3 Margins

Industry RankSector Rank
OM -4.36%
PM (TTM) -4.32%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MKD Yearly Profit, Operating, Gross MarginsMKD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 0 1 -1 -2 -3 -4

More info and screens

2

2. Health

2.1 Basic Checks

MKD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MKD has more shares outstanding
The debt/assets ratio for MKD has been reduced compared to a year ago.
MKD Yearly Shares OutstandingMKD Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 100M 200M 300M
MKD Yearly Total Debt VS Total AssetsMKD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 200M 400M 600M

2.2 Solvency

An Altman-Z score of 7.26 indicates that MKD is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of -0.29 indicates that MKD is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -0.29
Debt/FCF N/A
Altman-Z 7.26
ROIC/WACCN/A
WACC19.71%
MKD Yearly LT Debt VS Equity VS FCFMKD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 100M -100M -200M

2.3 Liquidity

MKD has a Current Ratio of 0.93. This is a bad value and indicates that MKD is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.92 indicates that MKD may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.92
MKD Yearly Current Assets VS Current LiabilitesMKD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for MKD have decreased strongly by -51.10% in the last year.
The Revenue for MKD has decreased by -42.49% in the past year. This is quite bad
MKD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.07% yearly.
EPS 1Y (TTM)-51.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69%
Revenue 1Y (TTM)-42.49%
Revenue growth 3Y21.82%
Revenue growth 5Y24.07%
Sales Q2Q%-67.08%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MKD Yearly Revenue VS EstimatesMKD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2B 4B 6B 8B 10B
MKD Yearly EPS VS EstimatesMKD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MKD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MKD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MKD Price Earnings VS Forward Price EarningsMKD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -3.17
MKD Per share dataMKD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MKD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOLECULAR DATA INC - ADR

NASDAQ:MKD (9/6/2022, 8:13:10 PM)

After market: 0.421 +0.01 (+2.68%)

0.41

+0.01 (+2.5%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustryInternet & Direct Marketing Retail
Earnings (Last)N/A N/A
Earnings (Next)09-27 2022-09-27/bmo
Inst Owners0.09%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap159.83M
Revenue(TTM)7.60B
Net Income(TTM)-328.00M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -3.17
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.78
BVpS-0.02
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.99%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -4.36%
PM (TTM) -4.32%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover9.96
Health
Industry RankSector Rank
Debt/Equity -0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.92
Altman-Z 7.26
F-Score2
WACC19.71%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69%
EPS Next Y98.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-42.49%
Revenue growth 3Y21.82%
Revenue growth 5Y24.07%
Sales Q2Q%-67.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

MOLECULAR DATA INC - ADR / MKD FAQ

Can you provide the ChartMill fundamental rating for MOLECULAR DATA INC - ADR?

ChartMill assigns a fundamental rating of 2 / 10 to MKD.


Can you provide the valuation status for MOLECULAR DATA INC - ADR?

ChartMill assigns a valuation rating of 2 / 10 to MOLECULAR DATA INC - ADR (MKD). This can be considered as Overvalued.


Can you provide the profitability details for MOLECULAR DATA INC - ADR?

MOLECULAR DATA INC - ADR (MKD) has a profitability rating of 1 / 10.


How financially healthy is MOLECULAR DATA INC - ADR?

The financial health rating of MOLECULAR DATA INC - ADR (MKD) is 3 / 10.